{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:38:40Z","timestamp":1746319120579,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NMRPG8G6102"],"award-info":[{"award-number":["NMRPG8G6102"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG8F0221"],"award-info":[{"award-number":["CMRPG8F0221"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10620-022-07657-8","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T12:02:54Z","timestamp":1660737774000},"page":"665-675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation"],"prefix":"10.1007","volume":"68","author":[{"given":"Shao-Ming","family":"Chiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuo-Chin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Houng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8896-8133","authenticated-orcid":false,"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,17]]},"reference":[{"key":"7657_CR1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","volume":"373","author":"YF Liaw","year":"2009","unstructured":"Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009;373:582\u2013592.","journal-title":"Lancet"},{"key":"7657_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","volume":"63","author":"AS Lok","year":"2016","unstructured":"Lok AS, McMahon BJ, Brown RS Jr et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology 2016;63:284\u2013306.","journal-title":"Hepatology"},{"key":"7657_CR3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jhep.2012.04.037","volume":"57","author":"A Ono","year":"2012","unstructured":"Ono A, Suzuki F, Kawamura Y et al. Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol. 2012;57:508\u2013514.","journal-title":"J Hepatol."},{"key":"7657_CR4","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.cgh.2015.06.002","volume":"13","author":"CH Chen","year":"2015","unstructured":"Chen CH, Hung CH, Hu TH et al. Association between level of hepatitis B surface antigen and relapse after entecavir therapy for chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2015;13:1984\u20131992.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"7657_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222221","volume":"14","author":"TL Ma","year":"2019","unstructured":"Ma TL, Hu TH, Hung CH et al. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. PLoS One. 2019;14:e0222221.","journal-title":"PLoS One."},{"key":"7657_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1021\/mp3002045","volume":"10","author":"D Babusis","year":"2013","unstructured":"Babusis D, Phan TK, Lee WA et al. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharm. 2013;10:459\u2013466.","journal-title":"Mol Pharm."},{"key":"7657_CR7","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK et al. 96 Weeks treatment of tenofovir alafenamide vs tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol. 2018;68:672\u2013681.","journal-title":"J Hepatol."},{"key":"7657_CR8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","volume":"1","author":"M Buti","year":"2016","unstructured":"Buti M, Gane E, Seto WK et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196\u2013206.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"7657_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HLY Chan","year":"2016","unstructured":"Chan HLY, Fung S, Seto WK et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. The Lancet Gastroenterology & Hepatology. 2016;1:185\u2013195.","journal-title":"The Lancet Gastroenterology & Hepatology."},{"key":"7657_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","volume":"6","author":"YF Liaw","year":"2012","unstructured":"Liaw YF, Kao JH, Piratvisuth T et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531\u2013561.","journal-title":"Hepatol Int."},{"key":"7657_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/00365521.2018.12027892","volume":"38","author":"CM Lee","year":"2003","unstructured":"Lee CM, Chen CH, Lu SN et al. Prevalence and Clinical Implications of Hepatitis B Virus Genotypes in Southern Taiwan. Scandinavian J Gastroenterol. 2003;38:95\u2013101.","journal-title":"Scandinavian J Gastroenterol."},{"key":"7657_CR12","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120:c179-184.","journal-title":"Nephron Clin Pract."},{"key":"7657_CR13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.cmi.2017.02.001","volume":"23","author":"IT Wu","year":"2017","unstructured":"Wu IT, Hu TH, Hung CH et al. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. Clin Microbiol Infect. 2017;23:464\u2013469.","journal-title":"Clin Microbiol Infect."},{"key":"7657_CR14","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.intimp.2016.11.022","volume":"42","author":"Y Han","year":"2017","unstructured":"Han Y, Zeng A, Liao H et al. The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis. Int Immunopharmacol. 2017;42:168\u2013175.","journal-title":"Int Immunopharmacol."},{"key":"7657_CR15","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/jvh.12851","volume":"25","author":"CH Chen","year":"2018","unstructured":"Chen CH, Hsu YC, Lu SN et al. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. J Viral Hepat. 2018;25:590\u2013597.","journal-title":"J Viral Hepat."},{"key":"7657_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/apt.15053","volume":"49","author":"MT Kuo","year":"2019","unstructured":"Kuo MT, Hu TH, Hung CH et al. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther. 2019;49:218\u2013228.","journal-title":"Aliment Pharmacol Ther."},{"key":"7657_CR17","first-page":"1162","volume":"17","author":"JC Wang","year":"2013","unstructured":"Wang JC, He LL, Chen Q. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir. Eur Rev Med Pharmacol Sci. 2013;17:1162\u20131168.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"7657_CR18","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1128\/AAC.00261-15","volume":"59","author":"CH Hung","year":"2015","unstructured":"Hung CH, Hu TH, Lu SN et al. Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation. Antimicrob Agents Chemother. 2015;59:3168\u20133173.","journal-title":"Antimicrob Agents Chemother."},{"key":"7657_CR19","first-page":"324","volume":"9","author":"J Hou","year":"2021","unstructured":"Hou J, Ning Q, Duan Z et al. 3-year treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for chronic HBV infection in China. J Clin Transl Hepatol. 2021;9:324\u2013334.","journal-title":"J Clin Transl Hepatol."},{"key":"7657_CR20","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/jvh.12833","volume":"25","author":"WJ Jeng","year":"2018","unstructured":"Jeng WJ, Chen YC, Liaw YF. Great and rapid HBsAg decline in patients with on-treatment hepatitis flare in early phase of potent antiviral therapy. J Viral Hepat. 2018;25:421\u2013428.","journal-title":"J Viral Hepat."},{"key":"7657_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/MEG.0000000000001733","volume":"32","author":"T Kumada","year":"2021","unstructured":"Kumada T, Toyoda H, Tada T et al. Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels. Eur J Gastroenterol Hepatol. 2021;32:255\u2013260.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"7657_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/jgh3.12443","volume":"5","author":"N Itokawa","year":"2021","unstructured":"Itokawa N, Atsukawa M, Tsubota A et al. Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B. JGH Open. 2021;5:34\u201340.","journal-title":"JGH Open."},{"key":"7657_CR23","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1111\/jgh.14686","volume":"34","author":"S Kaneko","year":"2019","unstructured":"Kaneko S, Kurosaki M, Tamaki N et al. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. J Gastroenterol Hepatol. 2019;34:2004\u20132010.","journal-title":"J Gastroenterol Hepatol."},{"key":"7657_CR24","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1002\/hep.23905","volume":"52","author":"K Wursthorn","year":"2010","unstructured":"Wursthorn K, Jung M, Riva A et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010;52:1611\u20131620.","journal-title":"Hepatology."},{"key":"7657_CR25","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.jhep.2014.07.019","volume":"6","author":"P Marcellin","year":"2014","unstructured":"Marcellin P, Buti M, Krastev Z et al. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol. 2014;6:1228\u20131237.","journal-title":"J Hepatol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07657-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-022-07657-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07657-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T07:52:54Z","timestamp":1675842774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-022-07657-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,17]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["7657"],"URL":"https:\/\/doi.org\/10.1007\/s10620-022-07657-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2022,8,17]]},"assertion":[{"value":"20 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}